Fig. 1 · Structure
Documents & Downloads
Bifikafusp alfa
Anticancer Agent
Bifikafusp alfa is a targeted immunotherapy fusion protein combining human L19 antibodies with interleukin 2 (IL-2). This reagent specifically binds to the EDB domain of fibronectin, enhancing its therapeutic potential in cancer treatment. Bifikafusp alfa exhibits significant anticancer activity, making it a valuable tool for research in tumor immunology and the development of novel cancer therapies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1957239-90-5 |
| Applications | Anticancer Agent |
| Molecular Weight | 84.058 kDa |
| Synonyms | L19-IL2 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.